Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.
复制标题
用JAK1/2抑制剂治疗的骨髓纤维化患者的能量消耗。
DOI：
10.3389/fendo.2023.1141029
复制
发表时间：
2023
影响因子：
5.2
通讯作者：
中科院分区：
文献类型：
--
作者：
体重增加是Ruxolitinib的已知副作用，它是一种JAK1/2抑制剂，是许多骨髓纤维化患者的主要治疗药物。鲁索利替尼增加体重背后的机制还不完全清楚，尽管已经提出了通过阻断下丘脑中瘦素的作用来减少脂肪组织脂解和增加食欲。为了探讨鲁索利替尼治疗骨髓纤维化患者的代谢变化，我们进行了一项先导性研究，以评估使用便携式间接量热计量化鲁索利替尼治疗前和治疗期间能量消耗的可行性，并报告了两名患者的结果。在鲁索利替尼治疗期间，两名患者的腰围都增加了。能源支出最初增加，然后减少，然后再次增加，但达到低于基线的水平。这些结果表明，Ruxolitinib继发的体重增加可能与全身能量消耗的变化有关。
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure.